scFv Antibody Fragments Targeting CCK-B Receptors for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic orofacial pain, particularly neuropathic pain, have a poor therapeutic response rate and often involve opioids, which come with addiction risks and limited efficacy, while also failing to effectively address associated anxiety and depression.
Innovation Solution
Development of a pharmaceutical composition comprising a therapeutic antibody, specifically a single-chain fragment variable (scFv) that targets the cholecystokinin B (CCK-B) receptor, which is involved in pain mediation, anxiety, and depression, using a modified cell-free ribosome display technology to generate high-affinity antibodies that can be administered to alleviate pain and anxiety-related behaviors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid treatments are used for chronic orofacial pain, then pain relief is achieved, but addiction risk increases and therapeutic response rate remains poor
Solution Approach 1:
The patent uses scFv antibody fragments as intermediary substances that specifically bind to and block CCK-B receptors in the trigeminal ganglia. This mediator approach provides pain relief through a different mechanism than opioids, avoiding addiction while maintaining therapeutic efficacy. The scFv acts as a targeted blocker that interferes with the CCK-CGRP complex formation, providing reliable pain management without the harmful side effects of opioid medications.
2Adaptability or versatility
If traditional pain treatments are used, then some pain relief is provided, but associated anxiety and depression are not effectively addressed
Solution Approach 1:
The scFv antibody treatment demonstrates multi-functionality by simultaneously addressing pain, anxiety, and depression. The patent shows that blocking CCK-B receptors with scFv not only reduces orofacial pain but also ameliorates associated anxiety and depression behaviors. This universal approach treats multiple symptoms through a single mechanism, making the therapy adaptable to complex chronic pain conditions that involve multiple psychological and physiological components.
3Measurement precision
If full-length antibodies are used, then high specificity is achieved, but tissue penetration and delivery efficiency are reduced
Solution Approach 1:
The patent segments the full-length antibody into smaller single-chain variable fragment (scFv) portions that retain the antigen-binding specificity while improving tissue penetration. The scFv fragment contains the variable regions (VH and VL) necessary for specific CCK-B receptor binding but lacks the bulky constant regions, enabling efficient delivery to trigeminal ganglia and better tissue penetration while maintaining high binding specificity.
Data Source
AI summary
A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.